524711 — Vista Pharmaceuticals Income Statement
0.000.00%
Last trade - 00:00- IN₹134.06m
- IN₹200.77m
- IN₹100.75m
Annual income statement for Vista Pharmaceuticals, fiscal year end - March 31st, INR millions except per share, conversion factor applied.
2021 March 31st | 2022 March 31st | 2023 March 31st | 2024 March 31st | 2025 March 31st | |
|---|---|---|---|---|---|
| Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
| Source: | ARS | ARS | ARS | ARS | PRESS |
| Standards: | IAS | IAS | IAS | IAS | — |
| Status: | Final | Final | Final | Final | Final |
| Revenue | |||||
| Total Revenue | 12.7 | 3.95 | 10 | 103 | 101 |
| Cost of Revenue | |||||
| Gross Profit | 5.36 | 0.28 | -18.2 | 14 | 17.3 |
| Selling / General / Administrative Expenses | |||||
| Depreciation and Amortization | |||||
| Other Operating Expenses | |||||
| Total Operating Expenses | 37.2 | 22.2 | 60.7 | 146 | 148 |
| Operating Profit | -24.6 | -18.3 | -50.6 | -42.9 | -47.7 |
| Total Net Non Operating Interest Income / Expense | |||||
| Other Net Non Operating Costs | |||||
| Net Income Before Taxes | -36.9 | -25.6 | -58.8 | -51.8 | -52.9 |
| Provision for Income Taxes | |||||
| Net Income After Taxes | -18.9 | -8.32 | -56.6 | -45.1 | -46.5 |
| Net Income Before Extraordinary Items | |||||
| Net Income | -18.9 | -8.32 | -56.6 | -45.1 | -46.5 |
| Income Available to Common Shareholders Excluding Extraordinary Items | |||||
| Income Available to Common Shareholders Including Extraordinary Items | |||||
| Diluted Net Income | -18.9 | -8.32 | -56.6 | -45.1 | -46.5 |
| Diluted Weighted Average Shares | |||||
| Basic EPS Including Extraordinary Items | |||||
| Diluted EPS Including Extraordinary Items | |||||
| Diluted EPS Excluding Extraordinary Items | |||||
| Normalised Income Before Taxes | |||||
| Normalised Income After Taxes | |||||
| Normalised Income Available to Common Shareholders | |||||
| Diluted Normalised EPS | -0.544 | -0.226 | -1.54 | -1.03 | -0.79 |